Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
14
PVLA Quote, Financials, Valuation and Earnings
Last price:
$81.63
Seasonality move
:
49.53%
Day range:
$81.46 - $85.70
52-week range:
$17.31 - $114.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
24.95x
Volume:
187.3K
Avg. volume:
255.8K
1-year change:
307.7%
Market cap:
$965.1M
Revenue:
--
EPS (TTM):
-$6.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PVLA
Palvella Therapeutics, Inc.
|
-- | -$0.91 | -- | -22.28% | $187.87 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
AXSM
Axsome Therapeutics, Inc.
|
$192.8M | -$0.75 | 58.1% | -49.24% | $213.19 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$55.6M | $1.50 | 29.84% | -74.47% | $243.44 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$312.7M | -$0.88 | 123.14% | -90.73% | $671.07 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.75 | 14.08% | 25.96% | $868.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PVLA
Palvella Therapeutics, Inc.
|
$81.54 | $187.87 | $965.1M | -- | $0.00 | 0% | -- |
|
AGEN
Agenus, Inc.
|
$2.92 | $12.33 | $105.5M | -- | $0.00 | 0% | 0.74x |
|
AXSM
Axsome Therapeutics, Inc.
|
$181.21 | $213.19 | $9.1B | -- | $0.00 | 0% | 15.89x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$183.83 | $243.44 | $3.6B | 88.48x | $0.00 | 0% | 14.40x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$464.71 | $671.07 | $10.6B | -- | $0.00 | 0% | 13.92x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$803.17 | $868.04 | $84.9B | 19.32x | $0.88 | 0.44% | 6.08x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PVLA
Palvella Therapeutics, Inc.
|
29.29% | -2.932 | 2.3% | 6.16x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.322 | 3.58% | 1.45x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
32.19% | 1.350 | 12.95% | 23.64x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.430 | 3.33% | 3.14x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.69% | -0.011 | 3.64% | 3.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PVLA
Palvella Therapeutics, Inc.
|
-- | -$10.2M | -86.19% | -101.06% | -- | -$7.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$103.6M | $54.1M | 5.15% | 5.72% | 46.85% | $4.8M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.2B | $898.6M | 13.66% | 14.93% | 23.13% | $880M |
Palvella Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PVLA or AGEN?
Agenus, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of -116.82%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PVLAPalvella Therapeutics, Inc.-- -$1.03 $54.7M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About PVLA or AGEN?
Palvella Therapeutics, Inc. has a consensus price target of $187.87, signalling upside risk potential of 130.4%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 322.37%. Given that Agenus, Inc. has higher upside potential than Palvella Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Palvella Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PVLAPalvella Therapeutics, Inc.15 0 0 AGENAgenus, Inc.2 1 0 -
Is PVLA or AGEN More Risky?
Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock PVLA or AGEN?
Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PVLA or AGEN?
Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Palvella Therapeutics, Inc.'s net income of -$11.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 0.74x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PVLAPalvella Therapeutics, Inc.-- -- -- -$11.3M AGENAgenus, Inc.0.74x -- $30.2M $63.9M
-
Which has Higher Returns PVLA or AXSM?
Axsome Therapeutics, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of -27.62%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital PVLAPalvella Therapeutics, Inc.-- -$1.03 $54.7M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About PVLA or AXSM?
Palvella Therapeutics, Inc. has a consensus price target of $187.87, signalling upside risk potential of 130.4%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $213.19 which suggests that it could grow by 18.89%. Given that Palvella Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PVLAPalvella Therapeutics, Inc.15 0 0 AXSMAxsome Therapeutics, Inc.16 1 0 -
Is PVLA or AXSM More Risky?
Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.011%.
-
Which is a Better Dividend Stock PVLA or AXSM?
Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PVLA or AXSM?
Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. Palvella Therapeutics, Inc.'s net income of -$11.3M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 15.89x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PVLAPalvella Therapeutics, Inc.-- -- -- -$11.3M AXSMAxsome Therapeutics, Inc.15.89x -- $171M -$47.2M
-
Which has Higher Returns PVLA or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of 10.18%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.
Company Gross Margin Earnings Per Share Invested Capital PVLAPalvella Therapeutics, Inc.-- -$1.03 $54.7M LGNDLigand Pharmaceuticals, Inc.89.7% $5.68 $1.4B -
What do Analysts Say About PVLA or LGND?
Palvella Therapeutics, Inc. has a consensus price target of $187.87, signalling upside risk potential of 130.4%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 32.43%. Given that Palvella Therapeutics, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PVLAPalvella Therapeutics, Inc.15 0 0 LGNDLigand Pharmaceuticals, Inc.6 0 0 -
Is PVLA or LGND More Risky?
Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock PVLA or LGND?
Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PVLA or LGND?
Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Palvella Therapeutics, Inc.'s net income of -$11.3M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 88.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 14.40x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PVLAPalvella Therapeutics, Inc.-- -- -- -$11.3M LGNDLigand Pharmaceuticals, Inc.14.40x 88.48x $115.5M $117.3M
-
Which has Higher Returns PVLA or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of -39.75%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital PVLAPalvella Therapeutics, Inc.-- -$1.03 $54.7M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About PVLA or MDGL?
Palvella Therapeutics, Inc. has a consensus price target of $187.87, signalling upside risk potential of 130.4%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $671.07 which suggests that it could grow by 44.41%. Given that Palvella Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PVLAPalvella Therapeutics, Inc.15 0 0 MDGLMadrigal Pharmaceuticals, Inc.11 2 0 -
Is PVLA or MDGL More Risky?
Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.010, suggesting its less volatile than the S&P 500 by 201.017%.
-
Which is a Better Dividend Stock PVLA or MDGL?
Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PVLA or MDGL?
Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Palvella Therapeutics, Inc.'s net income of -$11.3M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 13.92x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PVLAPalvella Therapeutics, Inc.-- -- -- -$11.3M MDGLMadrigal Pharmaceuticals, Inc.13.92x -- $287.3M -$114.2M
-
Which has Higher Returns PVLA or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Palvella Therapeutics, Inc.'s net margin of 21.74%. Palvella Therapeutics, Inc.'s return on equity of -101.06% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital PVLAPalvella Therapeutics, Inc.-- -$1.03 $54.7M REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B -
What do Analysts Say About PVLA or REGN?
Palvella Therapeutics, Inc. has a consensus price target of $187.87, signalling upside risk potential of 130.4%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Palvella Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Palvella Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PVLAPalvella Therapeutics, Inc.15 0 0 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is PVLA or REGN More Risky?
Palvella Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.
-
Which is a Better Dividend Stock PVLA or REGN?
Palvella Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Palvella Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PVLA or REGN?
Palvella Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Palvella Therapeutics, Inc.'s net income of -$11.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Palvella Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palvella Therapeutics, Inc. is -- versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PVLAPalvella Therapeutics, Inc.-- -- -- -$11.3M REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
